Collaborative Cardiovascular Drug Safety and Biomarker Research Program

The summary for the Collaborative Cardiovascular Drug Safety and Biomarker Research Program Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Collaborative Cardiovascular Drug Safety and Biomarker Research Program
	CFDA Number:	93.103
	CFDA Description:	Food and Drug Administration_Research
	Federal Agency Name:	Food and Drug Administration
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-FDA-OC-2006-1
	Document Type:	Modification to Previous Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	Mar 07, 2006
	Creation Date:	Mar 07, 2006
	Original Closing Date for Applications:	May 01, 2006
	Current Closing Date for Applications:	Information not provided
	Archive Date:	Information not provided
	Expected Number of Awards:	1
	Estimated Total Program Funding:	$750,000
	Federal Grant Award Ceiling:	$750,000
	Federal Grant Award Floor:	$0
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Competition is limited because of Congressional mandate, the mission of the Critical Path Institute, its established collaboration with the University of Utah, and the combined ability of these parties to leverage existing databases, specimen repositories, clinical and other technical expertise in support of this program.
Grant Description: Collaborative Cardiovascular Drug Safety and Biomarker Research Program---As Proposed by Congress and to be conducted under FDAs Critical Path Initiative: This collaborative research program is expected to be conducted in a multi-phased process, leveraging resources and expertise from the awardee, other collaborators, and FDA to address public health needs involving cardiovascular disease and biomarker research; Availability of Sole Source Cooperative Agreement; Request for Application: RFA-FDA-OC-2006-1; Catalog of Federal Domestic Assistance Number 93.103. The Food and Drug Administration (FDA), Office of the Commissioner (OC) is announcing its intent to accept and consider a single source application for the award of a Cooperative Agreement to the Critical Path Institute. FDA anticipates providing up to $750,000 (direct and indirect costs combined) in fiscal year 2006 to support this multi-phased research program that will include, but will not be limited to, the development of an infrastructure to support this program and subsequent related studies in cardiovascular disease and genomic/proteomic biomarker research, as stipulated by Congress. Subject to the availability of Federal funds and successful performance, an additional two years of support up to $750,000(direct and indirect costs combined) per year may be available.FDA will support the research covered by this notice under the authority of Section 301 of the Public Health Service (PHS) Act (42 U.S.C. 241). FDAs research program is described in the Catalog of Federal Domestic Assistance No. 93.103. Before entering into cooperative agreements, FDA carefully considers the benefits such agreements will provide to the public.The cooperative agreement ensures FDAs continued participation in the Collaborative Cardiovascular Drug Safety and Biomarker Research Program---As proposed by Congress and to be conducted under FDAs Critical Path Initiative: A goal of the Critical Path Initiative is to foster the development of new tools to both promote drug safety and accelerate the development of innovative new therapies, through appropriate collaboration with multiple parties. For further information or a copy of the complete Request for Applications (RFA) contact Cynthia Polit, Grants Management Officer, Division of Contracts and Grants Management (HFA500), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7180, e-mail: cynthia.polit@fda.hhs.gov . This RFA can be viewed on Grants.gov under "Grant Find." A copy of the complete RFA can also be viewed on the FDA website at http://www.fda.gov/oc/initiatives/criticalpath/. For issues regarding the programmatic and scientific aspects of this notice: Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, FDA, 5600 Fishers Lane, Room 1471 (HF-1) Rockville, MD 20857, 301-827-7867, email: wendy.sanhai@fda.hhs.gov.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: Cynthia Polit
Grants Management Officer
Phone 301-827-7180 Cynthia.Polit@FDA.HHS.GOV Cynthia.Polit@FDA.HHS.GOV
Similar Government Grants: • Assisting the Integrated Food Safety System's National Food/Feed Training Program (U54); • Evaluation of Salmonella in Symptomatic and Asymptomatic Pets: Study for the Vet-LRN Program (U18); • Specialized Centers of Research (SCOR) on Sex Differences (P50); • Novel Interventions and Collaborations to Improving the Safe Use of Medications (U01); • Alliance for Advancing a National Integrated Food Safety System (U18); • Support for Small Scientific Conference Grant Program; • Cooperative Agreement to Support the World Health Organization (WHO) International Programme on Chem...; • Clinical Studies of Safety and Effectiveness of Orphan Products; • FDA State Food Safety Task Force Conference; • Food Safety and Security Research - Rapid Methods Development